Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
“7-year CROWN update
After a median follow-up of 83 months, median PFS with first-line lorlatinib in advanced ALK+ NSCLC remains unreached vs 9.1 months with crizotinib (HR 0.19). Seven-year PFS: 55% vs 3%.
No new intracranial progression events occurred after 30 months on lorlatinib, reinforcing its durable CNS activity.”
Title: Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study
Authors: Tony S. Mok, Benjamin J. Solomon, Enriqueta Felip, Todd M. Bauer, Geoffrey Liu, Yasushi Goto, Yi-Long Wu, Ross A. Soo, Julien Mazieres, Filippo de Marinis, Dong-Wan Kim, I-Ming Wang, Jolanda Paolini, Anna Polli, Nada Rifi, Francesca Toffalorio, Alice T. Shaw
Read the Full Article.
You can also read:
PD-(L)1 Rechallenge in Advanced NSCLC: A Small Signal, but Not a New Standard
